@article{TAU3124,
author = {Premsant Sangkum and Rhamee Badr and Ege Can Serefoglu and Wayne J.G. Hellstrom},
title = {Dapoxetine and the treatment of premature ejaculation},
journal = {Translational Andrology and Urology},
volume = {2},
number = {4},
year = {2013},
keywords = {},
abstract = {Introduction: Premature ejaculation (PE) is the most common male sexual complaint. Off-label oral selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of PE. Dapoxetine is a short-acting SSRI specifically designed for on-demand use. The objective of this communication is to summarize the clinical and physiological evidence regarding the role of the serotonergic pathway and specifically dapoxetine in the treatment of PE.
Methods: A PubMed search was conducted on articles reporting data on dapoxetine for the treatment of PE. Articles describing the pathophysiology and treatment options for PE were additionally included for review.
Results: The etiology of PE is multi-factorial in nature. There are many treatment options for PE such as psychological/behavioral therapy, topical anesthetic agents, phosphodiesterase type 5 (PDE-5) inhibitors, and tramadol hydrochloride. SSRIs play a major role in PE treatment. Animal and clinical studies in addition to its pharmacokinetic document dapoxetine’s clinical efficacy and safety for on-demand treatment of PE.
Conclusions: Dapoxetine demonstrates clinical efficacy and a favorable side effect profile. Dapoxetine is currently the oral drug of choice for on-demand treatment of PE.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/3124}
}